Hosted on MSN15h
Relmada acquires Tourette’s therapy rights from Asarina
Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma.
Relmada Therapeutics acquires Sepranolone from Asarina Pharma
Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed ...
Psychedelic: Relmada acquires neurosteroid from Asarina
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on an acquisition, study results ...
pharmaphorum8d
Asarina folds as it ends search for Tourette's drug partner
The directors of Asarina Pharma have abandoned a search for a partner for Tourette's syndrome treatment sepranolone, saying they have no choice but to liquidate the company. Just over a year ago ...